» Articles » PMID: 9315537

Troponin I Phosphorylation in the Normal and Failing Adult Human Heart

Overview
Journal Circulation
Date 1997 Oct 7
PMID 9315537
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In the failing human heart myofibrillar calcium sensitivity of tension development is greater and maximal myofibrillar ATPase activity is less than in the normal heart. Phosphorylation of the cardiac troponin I (cTnI)-specific NH2-terminus decreases myofilament sensitivity to calcium, while phosphorylation of other cTnI sites decreases maximal myofibrillar ATPase activity.

Methods And Results: We examined cTnI phosphorylation in left ventricular myocardium collected from failing hearts at the time of transplant (n=20) and normal hearts from trauma victims (n=24). The relative amounts of actin, tropomyosin, and TnI did not differ between failing and normal myocardium. Using Western blot analysis with a monoclonal antibody (MAb) that recognizes the striated muscle TnI isoforms, we confirmed that the adult human heart expresses only cTnI. A cTnI-specific MAb recognized two bands of cTnI, designated cTnI1 and cTnI2, while a MAb whose epitope is located in the cTnI-specific NH2-terminus recognized only cTnI1. Alkaline phosphatase decreased the relative amount of cTnl1, while protein kinase A and protein kinase C increased cTnI1. The percentage of cTnI made up of cTnI1, the phosphorylated form of TnI, is greater in the normal than the failing human heart (P<.00).

Conclusions: This phosphorylation difference could underlie the reported greater myofibrillar calcium sensitivity of failing myocardium. The functional consequence of this difference may be an adaptive or maladaptive response to the lower and longer calcium concentration transient of the failing heart, eg, enhancing force development or producing ventricular diastolic dysfunction.

Citing Articles

Cardiac troponin I directly binds and inhibits mitochondrial ATP synthase with a noncanonical role in the post-ischemic heart.

Elezaby A, Lin A, Vijayan V, Pokhrel S, Kraemer B, Bechara L Nat Cardiovasc Res. 2024; 3(8):987-1002.

PMID: 39196031 PMC: 11700703. DOI: 10.1038/s44161-024-00512-1.


Clinical Biochemistry of Serum Troponin.

Gokhan I, Dong W, Grubman D, Mezue K, Yang D, Wang Y Diagnostics (Basel). 2024; 14(4).

PMID: 38396417 PMC: 10887818. DOI: 10.3390/diagnostics14040378.


Altering Calcium Sensitivity in Heart Failure: A Crossroads of Disease Etiology and Therapeutic Innovation.

Saad N, Mashali M, Repas S, Janssen P Int J Mol Sci. 2023; 24(24).

PMID: 38139404 PMC: 10744146. DOI: 10.3390/ijms242417577.


Dysregulated Autophagy and Sarcomere Dysfunction in Patients With Heart Failure With Co-Occurrence of P63A and P380S Variants.

Martin T, Pak H, Gerhard G, Merali S, Merali C, Lemster B J Am Heart Assoc. 2023; 12(24):e029938.

PMID: 38108245 PMC: 10863766. DOI: 10.1161/JAHA.123.029938.


Thin filament regulation of cardiac muscle power output: Implications for targets to improve human failing hearts.

Hanft L, Robinett J, Kalogeris T, Campbell K, Biesiadecki B, McDonald K J Gen Physiol. 2023; 155(5).

PMID: 37000170 PMC: 10067705. DOI: 10.1085/jgp.202213290.